JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265481

Human AGO1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

AGO1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Cell Culture - Human AGO1 knockout HeLa cell line (AB265481)
  • Cell Culture

Unknown

Cell Culture - Human AGO1 knockout HeLa cell line (AB265481)

Representative images of AGO1 knockout HeLa cells, low and high confluency examples (top left and right respectively) and wild-type HeLa cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Sanger Sequencing - Human AGO1 knockout HeLa cell line (AB265481)
  • Sanger seq

Unknown

Sanger Sequencing - Human AGO1 knockout HeLa cell line (AB265481)

Allele-1 : 1 bp deletion in exon 2.

Sanger Sequencing - Human AGO1 knockout HeLa cell line (AB265481)
  • Sanger seq

Unknown

Sanger Sequencing - Human AGO1 knockout HeLa cell line (AB265481)

Allele-2 : 1 bp insertion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265481-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265481-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265481 Human AGO1 knockout HeLa cell line", "number":"AB265481-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265481-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265481 Human AGO1 knockout HeLa cell line", "number":"AB265481-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
AGO1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Argonaute 1 (Ago1) also known as "agoone" is a protein that plays a central role in RNA silencing processes. It weighs around 97 kDa and is a component of the RNA-induced silencing complex (RISC). Ago1 is expressed in various tissues where it binds to small RNAs such as microRNAs (miRNAs) and small interfering RNAs (siRNAs) to guide these molecules in targeting complementary RNA sequences for gene silencing. Ago1's ability to slice or inhibit translation of target RNAs makes it important in gene expression regulation.
Biological function summary

Ago1 is essential in the regulation of gene expression at the post-transcriptional level. As part of the RISC complex it binds to small regulatory RNAs facilitating their role in either cleaving target RNAs or repressing their translation. This function affects numerous cellular processes including cell differentiation proliferation and development. Ago1 also interacts with other Argonaute family members like Ago2 which is directly involved in RNA cleavage. Together these proteins ensure precise regulation of gene expression.

Pathways

The functional activities of Ago1 are significant in the RNA interference (RNAi) and microRNA (miRNA) pathways. In the RNAi pathway Ago1 participates by associating with siRNAs to silence target genes. In the miRNA pathway it works with miRNAs to repress translation or degrade mRNA transcripts. Ago1 collaborates with proteins like Dicer which assists in processing miRNAs and siRNAs highlighting its integrated role within these regulatory systems.

Disruptions in Ago1 activity have implications in cancers and neurodegenerative diseases. In cancer altered expression of Ago1 can lead to improper regulation of gene silencing affecting tumor suppressor genes and oncogenes. In neurodegenerative diseases the dysregulation of miRNA pathways mediated by Ago1 links it to conditions like Alzheimer's disease. Other proteins like Ago2 also play roles in these diseases often working in concert with Ago1 to maintain cellular homeostasis and prevent disease progression.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com